Acutaas Chemicals Limited — PPTs, 30-04-2026: Investor Presentation

Acutaas Chemicals reported a stellar Q4 FY26! Revenue jumped 40.3% YoY to ₹432.8 Cr. Profit After Tax (PAT) more than doubled, soaring 114.1% YoY to ₹134.3 Cr, achieving a record 31.0% PAT margin. Full-year FY26 revenue grew 33% to ₹1,339.4 Cr, with PAT up 122.2% to ₹356.4 Cr.

Growth was fueled by a robust CDMO ramp-up in Pharma Intermediates (88% of FY26 revenue) and a solid recovery in the Semiconductor business within Specialty Chemicals. The company's strategy focuses on diversifying across high-growth verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO, aiming for multiple long-term growth engines. Cost efficiencies and an improved product mix also significantly boosted EBITDA, which rose 116% YoY in Q4 to ₹183.5 Cr.

Management is confident of achieving 25% revenue growth in FY27, entering the year from a strong position. FY26 also saw impressive returns with ROCE at 39.3% and ROE at 32.5%.